Selskabsmeddelelser

Company announcement 19_ 2023 Orphazyme will consolidate it share in a ratio of 1000_1

Nov 2, 2023

Company-announcement-19_-2023-Orphazyme-will-consolidate-it-share-in-a-ratio-of-1000_1. pdf

Read more

Company-announcement-18-2023-decisions-of-extraordinary-general-meeting

Nov 2, 2023

Company-announcement-18-2023-decisions-of-extraordinary-general-meeting. pdf

Read more

Notice to convence an extraordinary general meeting

Oct 11, 2023

Uploads/Company-announcement-17_2023-Notice-to-convence-an-extraordinary-general-meeting. pdf

Read more

Intention of reverse stock split

Oct 11, 2023

Uploads/Company-announcement-16_2023-Announcement-about-intention-of-reverse-stock-split. pdf

Read more

Restricted stock units_to board and management

Oct 6, 2023

Company-announcement-15_2023-Restricted-stock-units_to-board-and-management. pdf

Read more

Preliminary court approval on US Security class action case

Oct 6, 2023

Company-announcement-14_2023-Preliminary-court-approval-on-US-Security-class-action-case. pdf

Read more

New CEO appointed

Sep 20, 2023

Company-announcement-13_23-Orphazyme-appoints-Jakob-Bendtsen-as-new-CEO. pdf

Read more

Company announcement 12/2023 Interim Report First Half 2023

Sep 12, 2023

Company announcement 12/2023 Interim Report First Half 2023

Read more

Change in management

May 30, 2023

The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company.

Change in management

Read more

Major shareholder announcement

May 19, 2023

Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Scandinavian Investment Group A/S, that as of May 16, 2023, Scandinavian Investment Group A/S holds shares corresponding to 10.00% of the total share capital and voting rights in the Company.

Major shareholder announcement

Read more

1 ... 4 5 6 7 8 ... 27